SCHEMBL4132304

SCHEMBL4132304

CCOc1ccc(S(=O)(=O)c2cc(CCNC(=O)O)nn2-c2ccccc2F)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
CTSA P10619 2/20 0.39
DGAT1 O75907 1/20 0.36
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
GCK P35557 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.34
MAPT P10636 2/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
SCN9A Q15858 1/20 0.34
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
ACACB O00763 1/20 0.33
NAMPT P43490 2/20 0.33
POLB P06746 1/20 0.33
MME P08473 1/20 0.33
TP53 P04637 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135106 0.92 NAMPT (0.41) CYP3A4CTSAGCKALDH1A1SCN9A
SCHEMBL4130432 0.89 NAMPT (0.39) CYP3A4CTSAALDH1A1NAMPT
SCHEMBL4130559 0.86 GAA (0.39) DGAT1ALDH1A1NAMPTKMT2A
SCHEMBL4131510 0.84 EPHX2 (0.38) CYP3A4CTSASCN9ANAMPT
SCHEMBL3699035 0.84 CYP3A4 (0.36) CYP3A4CTSADGAT1PPARDPPARA
Hydrochloric Acid SCHEMBL4131938 0.83 GCK (0.36) CYP3A4CTSAGCKNPSR1ALDH1A1
SCHEMBL4125823 0.82 NAMPT (0.38) SCN9ANAMPT
SCHEMBL4131207 0.82 THRB (0.40) ALDH1A1HPGDMAPTTSHRNAMPT
SCHEMBL4126447 0.82 NAMPT (0.41) ALDH1A1TSHRNAMPTPOLBKMT2A
SCHEMBL4135640 0.82 NAMPT (0.37) ALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 CYP3A4 198/4885CTSA 26/4885DGAT1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.